Challenges and opportunities associated with the md anderson impact2 randomized study in precision oncology

HIGHLIGHTS

• who: Henry Hiep Vo from the In, it was believed that targeted therapy against tumor alterations would not be effective for patients with solid tumors owing to the rarity of individual molecular alterations and limited number of targeted drugsIn contrast, the field of hematologic malignancies had already advanced to treat patients with acute or chronic leukemias on the basis of their molecular profiles, and tissue biopsy and blood analysis were routinely used for diagnostic purposes and for monitoring residual disease or emergence of resistance to treatment. In, imatinib was approved by the US Food and Drug Administration . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.